BioCentury | Dec 15, 2014
Finance

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal...
BC Week In Review | Apr 15, 2013
Clinical News

Lidakol 10 percent n-docosanol data

LDAKA released additional results from a trial in 10 HIV-1 infected patients with KS (see BioCentury March 24, 1997). All 10 patients exhibited decreased lesion size after 3 months, and of 2 biopsies performed 1...
BC Week In Review | Jan 16, 2006
Company News

Avanir Pharmaceuticals sales and marketing update

Avanir Pharmaceuticals (AVN), San Diego, Calif.   Business: Infectious   AVN granted an undisclosed company exclusive Japanese development and marketing rights to docosanol 10% cream to treat cold sores. AVN will receive a license fee,...
BioCentury | Jan 16, 2006
Finance

Ebb & Flow

Drug Royalty Corp. started operations in 1992 with the intent of going public and then issuing stock to fund its purchases of royalty interests in drugs. The IPO part happened, but the company subsequently had...
BC Week In Review | Oct 11, 2004
Company News

Avanir, Aco Hud AB deal

Aco will exclusively manufacture and market AVN's docosanol 10% cream in Sweden, Norway, Denmark and Finland to treat cold sores. Aco plans to launch the product in 2005. Docosanol was approved in Sweden in 2003...
BC Week In Review | Nov 24, 2003
Clinical News

Abreva docosanol 10% cream regulatory update

The Swedish Medical Products Agency approved docosanol 10% cream as a topical treatment for cold sore infections. Sweden will act as AVN's Reference Member State for the EU mutual recognition process. The company said it...
BC Week In Review | May 5, 2003
Company News

Avanir, Drug Royalty deal

AVN received a $3.6 million payment from DRI under a 2002 deal in which AVN sold DRI a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN said...
BC Week In Review | Jan 6, 2003
Company News

Avanir Pharmaceuticals, Drug Royalty deal

AVN sold DRI a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN retains rights to 50% of royalties earned on sales of Abreva in excess of $62...
BioCentury | Jan 6, 2003
Finance

Ebb & Flow

Swiss venture capital firms HBM BioVentures and NMT New Medical Technologies are joining forces to create a firm with about CHF830 million ($640 million) under management. The merged firms, which both invest heavily in biotech...
BC Extra | Dec 26, 2002
Company News

DRI gets rights to Avanir's Abreva royalties

AVN sold Drug Royalty Corp. (TSE:DRI) a portion of its North American royalty stream on cold sore drug Abreva docosanol 10% cream. AVN received an initial payment of $20.5 million, and is eligible for an...
Items per page:
1 - 10 of 65